In this presentation, the following will be covered: explaining the molecular profile and mechanism of action of an IL-23 inhibitor, describing data handling rules and imputation methods, reviewing the clinical efficacy and safety data from clinical trials in patients with Active Psoriatic Arthritis, and understanding Real-World Evidence and review PsA data from multiple registries. Developed and offered by Janssen.
Non-CME
